Cargando…

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

IMPORTANCE: The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another. OBJECTIVE: To evaluate treatment class-specific outcomes of patients receiving immune checkpoint inhibitor (ICI) vs taxane chemotherapy by tumor mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Ryon P., Fisher, Virginia, Weberpals, Janick, Gjoerup, Ole, Tierno, Marni B., Huang, Richard S. P., Sayegh, Nicolas, Lin, Douglas I., Raskina, Kira, Schrock, Alexa B., Severson, Eric, Haberberger, James F., Ross, Jeffrey S., Creeden, James, Levy, Mia A., Alexander, Brian M., Oxnard, Geoffrey R., Agarwal, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972027/ https://www.ncbi.nlm.nih.gov/pubmed/35357449 http://dx.doi.org/10.1001/jamanetworkopen.2022.5394

Ejemplares similares

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
por: Zhang, Liangliang, et al.
Publicado: (2022)

Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
por: Lee, Jessica K., et al.
Publicado: (2021)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
por: Husain, Hatim, et al.
Publicado: (2022)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Artificial Intelligence for Prognostic Scores in Oncology: a Benchmarking Study
por: Loureiro, Hugo, et al.
Publicado: (2021)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
por: Lee, Jessica K., et al.
Publicado: (2022)

Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
por: Hill, Breana L, et al.
Publicado: (2023)

A systematic approach towards missing lab data in electronic health records: A case study in non‐small cell lung cancer and multiple myeloma
por: Sondhi, Arjun, et al.
Publicado: (2023)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
por: Schwartzberg, Lee S., et al.
Publicado: (2022)

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
por: Sammons, Sarah, et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case Report
por: Hemenway, Gregory, et al.
Publicado: (2022)

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
por: Chehrazi-Raffle, Alex, et al.
Publicado: (2023)

Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
por: Weberpals, Janick, et al.
Publicado: (2017)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients
por: Weberpals, Janick, et al.
Publicado: (2018)

EFFECT OF PREPUBERTY CASTRATION ON SUBSEQUENT CANCER IMPLANTATION
por: Murphy, James B., et al.
Publicado: (1925)

Castration the Remedy for Crime
por: Arbogast, B. A.
Publicado: (1895)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Viral Interference with DNA Repair by Targeting of the Single-Stranded DNA Binding Protein RPA
por: Banerjee, Pubali, et al.
Publicado: (2013)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
por: Sayegh, Nicolas, et al.
Publicado: (2023)

Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer
por: Graf, Ryon P., et al.
Publicado: (2021)

HEP directory on MAC FileMaker-II
por: Oxnard, B
Publicado: (1991)

Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis
por: Jindal, Tarun, et al.
Publicado: (2021)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation
por: Huang, Richard S P, et al.
Publicado: (2022)

Castration
por: Pugh, T. J.
Publicado: (1897)

RNaseH-mediated simultaneous piggyback knockdown of multiple genes in adult zebrafish
por: Raman, Revathi, et al.
Publicado: (2020)

Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors
por: Ramkissoon, Lori A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sgtd48dvhrr6b948dr9ks3l0qb